Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Inclusion Criteria: * Must have a clinical history of significant ragweed-induced allergic rhinoconjunctivitis of at least 2 years duration, with or without asthma and have received treatment during the previous RS. * Must have a positive skin prick test response to Ambrosia artemisiifolia at Screening Visit. * Must be positive for specific immunoglobulin E (IgE) against Ambrosia artemisiifolia at Screening Visit. * Must have an forced expiratory volume in 1 second (FEV1) of at least 70% of predicted at Screening Visit. * Safety laboratory tests and vital signs conducted at the Screening Visit must be within normal limits or clinically acceptable to the investigator/sponsor Exclusion Criteria: * Clinical history of symptomatic seasonal allergic rhinitis and/or asthma having received regular medication, due to another allergen during or potentially overlapping the RS. * Clinical history of significant symptomatic perennial allergic rhinitis and/or asthma due to an allergen to which the participant is regularly exposed. * Receipt of an immunosuppressive treatment within 3 months prior to the Screening Visit (except steroids for allergic and asthma symptoms). * Clinical history of severe asthma. * Asthma requiring medium or high dose inhaled corticosteroids. * History of anaphylaxis with cardiorespiratory symptoms. * History of chronic urticaria and angioedema. * Clinical history of chronic sinusitis 2 years prior to the Screening Visit. * Current severe atopic dermatitis. * …